TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26471977

Group type: EXPERIMENTAL
Intervention: Müller straight stem (MSS)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Virtec straight stem (VSS)
Number of subjects: 646
Study: 25666427

Group type: EXPERIMENTAL
Intervention: High-dose CDDP (810 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Mid-dose CDDP (540 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 23434737

Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (20, 40, or 80 μg of truncated glycoprotein D from HSV-2 strain)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different aluminum salts: AlPO₄ or Al(OH)₃)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different preservatives)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different volumes: 0.5 or 1 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations
Number of subjects: 150
Study: 20350333

Group type: EXPERIMENTAL
Intervention: Bosentan 500 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19122492

Group type: EXPERIMENTAL
Intervention: Strengthening program for the lower back (lumbar stabilization exercises and education on pain management) for 8 weeks, 3 days a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study: 16624552

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg daily)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Imatinib (general treatment)
Number of subjects: 377
Study: 14642458

Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM)
Number of subjects: 10
Study: 10962114

Group type: EXPERIMENTAL
Intervention: Batista procedure
Number of subjects: 0
Study: 9201637

Group type: EXPERIMENTAL
Intervention: Cryotherapy and exercises
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercises alone
Number of subjects: 45
Study: 1532316

Group type: EXPERIMENTAL
Intervention: 5 mg slow release oral isradipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2948162

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 30160335

Group type: EXPERIMENTAL
Intervention: Stimulation (n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham (n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal nerve block (used by 80% of subjects)
Number of subjects: 10
Study: 29259382

Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of tolvaptan vs furosemide
Number of subjects: 56
Study: 25850814

Group type: EXPERIMENTAL
Intervention: High-β-glucan tortillas
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High insoluble fibre tortillas
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-β-glucan tortillas
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low insoluble fibre tortillas
Number of subjects: 12
Study: 23293333

Group type: EXPERIMENTAL
Intervention: CoA 200 U/d (group B)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: CoA 400 U/d (group C)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 244
Study: 20552330

Group type: EXPERIMENTAL
Intervention: Lycopene-rich tomato juice
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lycopene capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (combined juice and capsules)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19567023

Group type: EXPERIMENTAL
Intervention: Chai Shao Liu Jun Tang in combination with Lamivudine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 405
Study: 17878255

Group type: EXPERIMENTAL
Intervention: Leptin levels in women (12.5 ng/ml)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in women (0.75 mg/liter)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Correlation between CRP and leptin in women
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Correlation between CRP and leptin in men
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Leptin as a determinant of CRP in men
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Leptin as a determinant of CRP in women
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Mendelian randomization test for CRP as a causal agent for leptin
Number of subjects: 1862
Study: 15268895

Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study: 12402413

Group type: EXPERIMENTAL
Intervention: Serial echocardiograms and obstetric sonograms performed at least every 2 weeks starting from 16 weeks gestation in anti-Ro/SSA positive pregnant women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal antibodies anti-Ro/SSA and anti-La/SSB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term outcomes for mothers and affected children
Number of subjects: 0
Study: 10682131

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatments
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study: 8272312

Group type: EXPERIMENTAL
Intervention: Vitamin K and phenobarbital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2456174

Group type: EXPERIMENTAL
Intervention: Iloprost at a dose of 2 ng/kg/min for 6 hours daily for 6 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Iloprost at a dose of 1 ng/kg/min for 6 hours daily for 6 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study: 30855096

Group type: EXPERIMENTAL
Intervention: I-CXL
Number of subjects: 60

Group type: COMPARATOR
Intervention: S-CXL
Number of subjects: 60

Group type: COMPARATOR
Intervention: I-SCXL
Number of subjects: 60
Study: 29017162

Group type: EXPERIMENTAL
Intervention: Patiromer without food
Number of subjects: 112

Group type: COMPARATOR
Intervention: Patiromer with food
Number of subjects: 112
Study: 24973862

Group type: EXPERIMENTAL
Intervention: 1000 mg omega‐3 fatty acid supplements (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 56
Study: 23921301

Group type: EXPERIMENTAL
Intervention: Therapeutic cangrelor
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Supratherapeutic cangrelor
Number of subjects: 67

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 20868638

Group type: EXPERIMENTAL
Intervention: EGb-761, 240 mg/d
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 19246729

Group type: EXPERIMENTAL
Intervention: nelfinavir 1250 mg every 12 hours on days 1-4
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: nelfinavir 1250 mg every 12 hours on days 1-3 plus 3125 mg on day 4
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg every 24 hours on days 1-4
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 16618915

Group type: COMPARATOR
Intervention: Azithromycin (500 mg daily for 3 days)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg daily for 5 days)
Number of subjects: 105
Study: 15585764

Group type: EXPERIMENTAL
Intervention: Cystine intake of 5 mg.kg(‐1).d(‐1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cystine intake of 12 mg.kg(‐1).d(‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0 mg cystine intake (previously estimated)
Number of subjects: 21
Study: 11384708

Group type: EXPERIMENTAL
Intervention: Depressed subjects (BDI score >14)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Nondepressed subjects (BDI score ≤14)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 155
Study: 9480466

Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (7.5-15 mg weekly)
Number of subjects: 96
Study: 8492409

Group type: EXPERIMENTAL
Intervention: Regimen A (intermediate dose cytosine arabinoside (Ara‐C), cyclophosphamide (CPM) plus 6MP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Regimen B (high-dose Ara‐C plus CPM)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 188

Group type: COMPARATOR
Intervention: Regimen B
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Patients with initial leukocyte count > or = 10 x 10(4)/microliters
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Patients with leukocyte count < 10 x 10(4)/microliter
Number of subjects: 188
Study: 3284399

Group type: EXPERIMENTAL
Intervention: Raw untreated cow milk
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pasteurized cow milk
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Homogenized and pasteurized cow milk
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nutramigen (placebo)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Skin prick tests with raw cow milk protein extract
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nutramigen (skin prick test)
Number of subjects: 5
Study: 31818531

Group type: EXPERIMENTAL
Intervention: 10 g of refined cold-pressed flaxseed oil providing 4.7 g ALA (n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 10 g of high-oleic sunflower oil (control) (n = 30)
Number of subjects: 59
Study: 29019418

Group type: EXPERIMENTAL
Intervention: Standard care plus daily motivational interviewing-based text messages
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study: 28961714

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole 300 mg twice daily on day 1, followed by 300 mg once daily for 4-28 days, then oral posaconazole 400 mg twice daily or 200 mg three times daily for 28 days.
Number of subjects: 237
Study: 26290323

Group type: EXPERIMENTAL
Intervention: Operative treatment with concentrated blood and bone marrow aspirate (cB + cBMA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Operative treatment without cB + cBMA (sham treatment)
Number of subjects: 50
Study: 23406601

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF) and intraocular placebo (PL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal placebo (PL) and intraocular olopatadine (OLO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF) and intraocular olopatadine (OLO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal placebo (PL) and intraocular placebo (PL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF)
Number of subjects: 0
Study: 20464787

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 80
Study: 18001177

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (ATDs) therapy in Graves' disease
Number of subjects: 57

Group type: COMPARATOR
Intervention: Antithyroid drugs (ATDs) therapy in painless thyroiditis
Number of subjects: 57
Study: 17110267

Group type: EXPERIMENTAL
Intervention: Acrylic cap splint type expansion appliances covering all dentition except the incisors and canine on the shifted side.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acrylic cap splint type expansion appliances covering only the posterior teeth, from the first premolars on both sides.
Number of subjects: 32
Study: 15256294

Group type: EXPERIMENTAL
Intervention: Massage therapy (30-min massages three times per week for 5 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 34
Study: 11399342

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study: 9416722

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg (three times the ED95)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Succinylcholine 2 mg/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.8 mg/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 78
Study: 8236504

Group type: EXPERIMENTAL
Intervention: RT plus NTX (100 mg every other day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 21
Study: 3828273

Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 0
Study: 30326548

Group type: EXPERIMENTAL
Intervention: Carriage of an ALDH2 rs671 A allele
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Carriage of an A allele in males
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Carriage of an A allele in moderate drinkers
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Increasing alcohol consumption by 1.7-fold
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Elevated alcohol intake
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 4536

Group type: EXPERIMENTAL
Intervention: Alcohol intake in females
Number of subjects: 4536
Study: 29166200

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no audiovisual distraction)
Number of subjects: 38
Study: 26687126

Group type: EXPERIMENTAL
Intervention: Single-visit treatment
Number of subjects: 220

Group type: COMPARATOR
Intervention: Multiple-visit treatment
Number of subjects: 220
Study: 23657296

Group type: EXPERIMENTAL
Intervention: 1-year diet and physical activity intervention with sodium restriction
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: 1-year diet and physical activity intervention without sodium restriction
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Subgroup with metabolic syndrome (n=98)
Number of subjects: 285
Study: 21290248

Group type: EXPERIMENTAL
Intervention: Racemic cyclophosphamide (CYC) 900 or 1,000 mg/m²
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Racemic cyclophosphamide (CYC)
Number of subjects: 15
Study: 19717250

Group type: EXPERIMENTAL
Intervention: Contingency management with clinic-delivered, abstinence-based incentive program and weekly behavioral parent training sessions
Number of subjects: 69

Group type: COMPARATOR
Intervention: Attendance-based incentive program and weekly psychoeducational parent sessions (Control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both conditions (MET/CBT and drug-testing program)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Negative parenting (predictor)
Number of subjects: 69
Study: 17704421

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery (preoperative cisplatin plus fluorouracil)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy after R1 resection
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Objective tumor regression after preoperative chemotherapy
Number of subjects: 443
Study: 14715820

Group type: EXPERIMENTAL
Intervention: Orbital irradiation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 88
Study: 11676944

Group type: COMPARATOR
Intervention: Thrombolysis in grade II group
Number of subjects: 894

Group type: COMPARATOR
Intervention: Angioplasty in grade II group
Number of subjects: 894

Group type: COMPARATOR
Intervention: Thrombolysis in grade III group
Number of subjects: 894

Group type: COMPARATOR
Intervention: Angioplasty in grade III group
Number of subjects: 894

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 894

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 894
Study: 9174871

Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 7951683

Group type: EXPERIMENTAL
Intervention: Short form of the CAMDEX interview
Number of subjects: 134

Group type: COMPARATOR
Intervention: Full form of the CAMDEX interview
Number of subjects: 134
Study: 2442415

Group type: EXPERIMENTAL
Intervention: Sodium pentosanpolysulfate (200 mg twice daily)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 31937532

Group type: EXPERIMENTAL
Intervention: Morning warfarin ingestion
Number of subjects: 217

Group type: COMPARATOR
Intervention: Evening warfarin ingestion
Number of subjects: 217

Group type: COMPARATOR
Intervention: Comparison of morning vs evening
Number of subjects: 217

Group type: COMPARATOR
Intervention: Comparison of percent change in proportion of time outside therapeutic INR range
Number of subjects: 217
Study: 31037289

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg intravitreous injection, n = 226)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (n = 240)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Observation (n = 236)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Aflibercept (for eyes in laser photocoagulation or observation groups with decreased visual acuity)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Adverse events (Antiplatelet Trialists' Collaboration)
Number of subjects: 702
Study: 27764527

Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Number of subjects: 0
Study: 26703491

Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD1 multifocal IOL
Number of subjects: 39

Group type: COMPARATOR
Intervention: Acrysof IQ monofocal IOL
Number of subjects: 39
Study: 23575197

Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) treatment
Number of subjects: 1797
Study: 21751942

Group type: EXPERIMENTAL
Intervention: THI-12 total score
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: THI-12 three-factorial structure
Number of subjects: 618
Study: 19803620

Group type: EXPERIMENTAL
Intervention: Family intervention to improve medication adherence and reduce relapse
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 144
Study: 17103307

Group type: EXPERIMENTAL
Intervention: 15 g L-Arg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30 g L-Arg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 14523338

Group type: EXPERIMENTAL
Intervention: 0.05% GTN ointment
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.1% GTN ointment
Number of subjects: 15
Study: 10636519

Group type: EXPERIMENTAL
Intervention: One double-bite suture on each side of the urethra (Group A)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Two single-bite sutures on each side of the urethra (Group B)
Number of subjects: 161
Study: 8708839

Group type: EXPERIMENTAL
Intervention: Hydrocath (22-gauge hydrophilic coated polyurethane catheter)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Silastic catheter (23-gauge silastic catheter)
Number of subjects: 58
Study: 1559321

Group type: EXPERIMENTAL
Intervention: Disopyramide (D.RET.) 250 mg twice daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amiodarone 1200 mg daily for 10 days, then 200 mg daily
Number of subjects: 76
Study: 4014620

Group type: EXPERIMENTAL
Intervention: 60 mg controlled-release oral morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 90 mg controlled-release oral morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 15 mg intramuscular morphine
Number of subjects: 30
Study: 31285591

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab (BEV)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus cetuximab (CET)
Number of subjects: 122
Study: 29739782

Group type: EXPERIMENTAL
Intervention: Digital self‐management intervention for blood pressure self‐monitoring and medication change
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Digital self‐management intervention
Number of subjects: 35
Study: 26265465

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme (aerobic and strength training)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Regular antenatal care (Control)
Number of subjects: 855
Study: 24894436

Group type: EXPERIMENTAL
Intervention: Integrated pain management program supplemented with peer volunteers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 30
Study: 22477640

Group type: EXPERIMENTAL
Intervention: Fractionated inpatient rehabilitation programme with aftercare
Number of subjects: 411

Group type: COMPARATOR
Intervention: Standard rehabilitation programme without aftercare
Number of subjects: 411
Study: 20200423

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard genetic counseling (SGC)
Number of subjects: 90
Study: 17470398

Group type: EXPERIMENTAL
Intervention: Errorless (implicit) learning method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Errorful (explicit) learning method
Number of subjects: 0
Study: 15843729

Group type: COMPARATOR
Intervention: Celecoxib (Celebrex)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin (Indocid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 12032741

Group type: EXPERIMENTAL
Intervention: Herbal treatment (90 mg ephedrine alkaloids and 192 mg caffeine per day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 11078251

Group type: EXPERIMENTAL
Intervention: Rhythm regularization following direct-current cardioversion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atrial fibrillation (irregular rhythm)
Number of subjects: 10
Study: 8641638

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1467659

Group type: EXPERIMENTAL
Intervention: Local intravaginal application of metronidazole (500 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Single-shot prophylaxis with cefuroxime (1,500 mg intravenously)
Number of subjects: 114